Bone metabolic stress, suboptimal musculoskeletal adaptation, and muscle function changes associated with high-intensity training in adolescent basketball players Musculoskeletal Diseases
Conditions
Interventions
Eligible participants are randomly assigned in a 1:1 ratio to either the intervention group or the placebo group. The randomisation sequence is generated by an independent statistician using a compute
Sponsors
Chizhou University
Eligibility
Sex/Gender
All
Age
14 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Aged 14–18 years 2. Male or female adolescent basketball players 3. Systematic basketball training for =3 years 4. Current training volume =15 hours/week 5. Bone age within 1 year of chronological age 6. Good general health and able to complete all study assessments 7. Written informed consent from both participant and legal guardian
Exclusion criteria
Exclusion criteria: 1. History of metabolic bone disease 2. Fracture within the past 6 months 3. Endocrine disorders affecting bone metabolism 4. Use of medications affecting bone metabolism within the past 3 months 5. Severe gastrointestinal disease 6. Allergy to study product ingredients 7. Participation in another clinical trial during the study period
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1. Serum C-terminal telopeptide of type I collagen concentration (CTX-1) measured from fasting morning blood samples using a validated laboratory immunoassay at baseline and week 16. 2. Serum bone-specific alkaline phosphatase concentration (BALP) measured from fasting morning blood samples using a validated laboratory assay at baseline and week 16. 3. The P1NP/CTX-1 ratio is calculated from serum P1NP and CTX-1 values at baseline and week 16. 4. Bone mineral density is measured using dual-energy X-ray absorptiometry (DXA) at baseline and week 16. 5. Bone microstructure is measured using high-resolution peripheral quantitative computed tomography (HR-pQCT) at baseline and week 16. Parameters include trabecular bone volume fraction, trabecular thickness, trabecular number, cortical thickness, cortical bone mineral density, estimated stiffness and estimated failure load. 6. Knee extensor muscle strength is measured using isokinetic dynamometry with the Biodex system at baseline and week 16. 7. Functional performance is measured using vertical jump height and 20-metre sprint time at baseline and week 16. 8. Muscle-bone adaptation biomarkers, including myostatin, irisin, insulin-like growth factor-1, undercarboxylated osteocalcin and fibroblast growth factor-23, are measured from fasting blood samples using validated laboratory assays at baseline and week 16. 9. Safety and tolerability are assessed using adverse event records, gastrointestinal symptom scores, liver function tests, kidney function tests, serum calcium and urinary calcium/creatinine ratio during the intervention period, including baseline, weeks 4, 8, 12 and 16, and the week 20 follow-up assessment. | — |
Countries
China
Contacts
Public ContactLei;Shun He;Yue
;
Outcome results
None listed